These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 19035448)
1. HPV16/18 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness. Coupé VM; van Ginkel J; de Melker HE; Snijders PJ; Meijer CJ; Berkhof J Int J Cancer; 2009 Feb; 124(4):970-8. PubMed ID: 19035448 [TBL] [Abstract][Full Text] [Related]
2. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium. Demarteau N; Van Kriekinge G; Simon P Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952 [TBL] [Abstract][Full Text] [Related]
3. How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands. Coupé VM; de Melker HE; Snijders PJ; Meijer CJ; Berkhof J Vaccine; 2009 Aug; 27(37):5111-9. PubMed ID: 19567242 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras. Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157 [TBL] [Abstract][Full Text] [Related]
5. The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands. Bogaards JA; Coupé VM; Meijer CJ; Berkhof J Vaccine; 2011 Nov; 29(48):8929-36. PubMed ID: 21945961 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. de Kok IM; van Ballegooijen M; Habbema JD J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256 [TBL] [Abstract][Full Text] [Related]
7. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model. Gomez JA; Lepetic A; Demarteau N BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716 [TBL] [Abstract][Full Text] [Related]
8. Cost-Utility of a Two-Dose Human Papillomavirus Vaccination Programme Added to Cervical Cancer Screening Compared with Cervical Cancer Screening Alone in Korea. Lee H; Hur S; Jang H; Lee IH; Sohn WY; Van Kriekinge G; Kim BG Asian Pac J Cancer Prev; 2019 Feb; 20(2):425-435. PubMed ID: 30803204 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of human papilloma virus vaccination in Iceland. Oddsson K; Johannsson J; Asgeirsdottir TL; Gudnason T Acta Obstet Gynecol Scand; 2009; 88(12):1411-6. PubMed ID: 19900074 [TBL] [Abstract][Full Text] [Related]
10. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule. Germar MJ; Purugganan C; Bernardino MS; Cuenca B; Chen YC; Li X; Van Kriekinge G; Lee IH Hum Vaccin Immunother; 2017 May; 13(5):1158-1166. PubMed ID: 28075249 [TBL] [Abstract][Full Text] [Related]
12. The value of male human papillomavirus vaccination in preventing cervical cancer and genital warts in a low-resource setting. Sharma M; Sy S; Kim JJ BJOG; 2016 May; 123(6):917-26. PubMed ID: 26176301 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia. Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary. Vokó Z; Nagyjánosi L; Kaló Z BMC Public Health; 2012 Oct; 12():924. PubMed ID: 23110361 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore. Tay SK; Lee BW; Sohn WY; Lee IH; Mathur G; Sanicas M; Van Kriekinge G Singapore Med J; 2018 Jul; 59(7):370-382. PubMed ID: 28983579 [TBL] [Abstract][Full Text] [Related]
16. Mathematical models of cervical cancer prevention in the Asia Pacific region. Goldie SJ; Diaz M; Kim SY; Levin CE; Van Minh H; Kim JJ Vaccine; 2008 Aug; 26 Suppl 12():M17-29. PubMed ID: 18945411 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil. Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154 [TBL] [Abstract][Full Text] [Related]
18. Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness? de Kok IM; Habbema JD; van Rosmalen J; van Ballegooijen M Eur J Cancer; 2011 Feb; 47(3):428-35. PubMed ID: 20971633 [TBL] [Abstract][Full Text] [Related]
19. A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines. Guerrero AM; Genuino AJ; Santillan M; Praditsitthikorn N; Chantarastapornchit V; Teerawattananon Y; Alejandria M; Toral JA BMC Public Health; 2015 Jul; 15():730. PubMed ID: 26223975 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence. Li X; Stander MP; Van Kriekinge G; Demarteau N BMC Infect Dis; 2015 Dec; 15():566. PubMed ID: 26652918 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]